PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (α-MSH). It was born out of Melanotan II research in the 1980s at the University of Arizona, where scientists were developing tanning agents and kept noticing that test subjects were getting spontaneous erections.
Unlike Viagra, Cialis, and other PDE5 inhibitors that work by increasing blood flow to the penis (a peripheral, mechanical effect), PT-141 works upstream in the brain. It activates melanocortin receptors MC1R, MC3R, MC4R, and MC5R (it skips MC2R, which only responds to ACTH). The therapeutic effect comes mainly from MC4R in the hypothalamus, which is the primary switch for sexual arousal, directly triggering dopamine release in the medial preoptic area and flipping the neurological switch for desire. MC3R plays a supporting role, it's more involved in energy balance and how the body partitions calories between fat and lean mass, but it modulates how strongly MC4R signals propagate, essentially setting the sensitivity of the trigger that MC4R pulls. MC1R activation is what causes the skin darkening side effect (same receptor your body uses to tan), and MC5R hits sebaceous glands (oil production, not commonly noticeable). The nausea also comes from MC4R, just in a different part of the brain, the area postrema in the brainstem, which sits outside the blood-brain barrier to detect toxins.
This is the only FDA-approved drug that directly targets the central nervous system pathway for sexual desire. Approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use in men for ED and low libido is growing rapidly, particularly for men who don't respond to PDE5 inhibitors.
The key distinction is that PDE5 inhibitors require you to already be sexually stimulated to work (they just maintain the erection). PT-141 generates the desire and arousal signal itself from the brain down. This makes it uniquely effective for people whose issue is psychological, neurogenic, or desire-based rather than purely vascular.
It also doesn't interact with alcohol (unlike flibanserin, the other HSDD drug), which is a practical advantage.
In women, the RECONNECT phase 3 trials (two identical double-blind, placebo-controlled studies, 1,267 women, 24 weeks) showed significant improvements in sexual desire and significant reductions in distress related to low desire (both p < 0.001). About 58% of women on bremelanotide were classified as responders versus roughly 35% on placebo.
In men, a randomised controlled trial of 342 men who had failed sildenafil found that 34% in the bremelanotide group could achieve and maintain erections sufficient for intercourse, compared to just 9% on placebo. Another study found that co-administering low-dose PT-141 with sildenafil produced a significantly greater erectile response than sildenafil alone, suggesting the two work synergistically through completely different pathways. Early dose-ranging work showed significant erectile responses at doses above 1 mg subcutaneously, with onset at around 30 minutes.
A Phase IIB trial in men with diabetes-induced ED reported significant increases in erectile function scores, which matters because diabetic ED is notoriously difficult to treat with PDE5 inhibitors alone.
Real-world prescribing data from a urology clinic showed a 73% refill rate over 18 months in men, meaning the vast majority found it worth continuing.
Palatin Technologies currently (as of March 2026) has an active Phase II trial for bremelanotide in male ED, with Phase III planned if results hold.